Stocktoria
Bionano Genomics, Inc. BNGO
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2018-08-01
Bionano Genomics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -116.9% | -337.9% | -596.0% | -473.7% | -428.8% |
| Net margin | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% |
| Return on assets | -35.9% | -146.1% | -108.4% | -43.1% | -19.2% |
| Return on equity | -59.4% | -316.7% | -241.8% | -53.2% | -21.5% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 1.98 | 1.06 | 1.40 | 4.38 | 12.47 |
| Revenue growth | -7.4% | -14.8% | 29.9% | 54.6% | 111.5% |
Source: SEC EDGAR filings · CIK 0001411690 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.